**Supplementary Table S3. Tumor response in anti-PD1 antibody plus multikinase inhibitor**

|  |  |  |
| --- | --- | --- |
|  | **REGONIVO** | **LENPEM** |
|  | **All** | **Liver metastases** | ***P\**** | **All** | **Liver metastases** | ***P\**** |
|  |  | **-** | **+** |  |  | **-** | **+** |  |
| Number | 25 | 10 | 15 |  | 29 | 16 | 13 |  |
| Measurable lesion+ | 25 | 10 | 15 |  | 29 | 16 | 13 |  |
| CR | 1 | 1 | 0 |  | 1 | 0 | 1 |  |
| PR | 10 | 4 | 6 |  | 19 | 13 | 6 |  |
| SD | 11 | 3 | 8 |  | 9 | 3 | 6 |  |
| PD | 3 | 2 | 1 |  | 0 | 0 | 0 |  |
| NE | 0 | 0 | 0 |  | 0 | 0 | 0 |  |
| ORR (%) | 44% | 50% | 40% | 0.6968 | 69% | 81% | 54% | 0.2256 |
| DCR (%) | 88% | 80% | 93% | 0.5435 | 100% | 100% | 100% | -\*\* |

Abbreviations: REGONIVO, Regorafenib plus nivolumab; LENPEM, Lenvatinib plus pembrolizumab;

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated; ORR, objective response rate; DCR, disease control rate

\*Fisher’s exact test was used to compare ORR and DCR.

\*\*Fisher’s exact test was unpredictable.